MRI肝胆特异性对比剂Gd-EOB-DTPA对小肝细胞癌的诊断研究进展

摘要

肝细胞癌(HCC)是常见的原发性肝脏恶性肿瘤,全球的发病率逐年增长.HCC的早期发现与及时治疗是提高病人预后及生存率的关键.钆塞酸二钠(Gd-EOB-DTPA)是一种新型的MRI肝胆特异性对比剂,不仅具有普通细胞外间隙对比剂的功能,还可被肝细胞特异性摄取,进而提供肝胆期信息.Gd-EOB-DTPA增强MRI对HCC的诊断价值优于常规细胞外间隙对比剂增强MRI.就Gd-EOB-DTPA增强MRI在小HCC诊断及鉴别诊断中的应用现状进行综述.%Hepatocellular carcinoma (HCC) is a common primary malignant tumor of the liver in the world, and the morbidity of HCC is increasing year by year. Early diagnosis and timely treatment of HCC is critical to improve the prognosis and survival rate of the patients. Gd-EOB-DTPA is a new hepatocyte-specific contrast agent.It not only has the nature of non-specific extracellular space contrast medium, also can be further specifically taken up by hepatocytes, and it can provide the information of the hepatobiliary phase. The value of Gd-EOB-DTPA enhanced MRI in the diagnosis of HCC is superior to that of conventional extracellular space contrast agent enhanced MRI. We summarized the application status of Gd-EOB-DTPA enhanced MRI in diagnosis and differential diagnosis of small hepatocellular carcinoma.